Assessing Novel Therapeutically Active Anti-TNFR2 Agonistic Antibodies in Promoting Treg Proliferation and the Induction of Treg Functional Markers
Time: 11:30 am
day: Day 1 Treg Modulators track AM
Details:
- Illuminating the unique properties of TNFR2 agonism for Treg targeted therapies
- Optimizing TNFR2 targeting on Tregs with novel approaches
- Showcasing preclinical data from Nektar’s differentiated TNFR2 agonist
